Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation

Bone Marrow Transplantation

Volumn 25, Issue 12, 2000, Pages 1219-1222

  Copelan, E A ^a,b   Penza, S L ^a   Elder, P J ^a   Ezzone, S A ^a   Scholl, M D ^a   Bechtel, T P ^a   Belt, P S ^a   Avalos, B R ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Allogeneic transplantation; BuCy; Myelodysplastic syndrome

Indexed keywords

ANTILEUKEMIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; PHENYTOIN;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CELL TRANSFORMATION; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG TOXICITY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA; LIVER VEIN OBSTRUCTION; MALE; MYELODYSPLASTIC SYNDROME; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SCHOOL CHILD; SURVIVAL RATE;

EID: 0033920696     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702432     Document Type: Article

References (28)

1. Cheson BD. The myelodysplastic syndromes: current approaches to therapy. Ann Intern Med 1990; 112: 932-941.
2. Anderson JE, Appelbaum FR, Fisher LD et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993; 82: 677-681.
3. Anderson JE, Appelbaum FR, Storb R. An update on allogeneic marrow transplantation for myelodysplastic syndrome. Leuk Lymphoma 1995; 17: 95-99.
4. Anderson JE, Appelbaum FR, Schoch G et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood 1996; 87: 51-58.
5. Ratanatharathorn V, Karanes C, Uberti J et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplaslic syndromes. Blood 1993; 81: 2194-2199.
6. Anderson JE, Appelbaum FR, Schoch G et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14: 220-226.
7. Locatelli F, Niemeyer C, Angelucci E et al. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on myelodysplastic syndrome in childhood. J Clin Oncol 1997; 15: 566-573.
8. Gluckberg H, Storb R, Fefer A et al. Clinical manifestation of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
9. Shulman HM, Sale GE, Lerner KG et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol 1978; 19: 545-570.
10. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 11: 255-267.
11. Clark JG, Crawford SW, Madtes DK, Sullivan KM. Obstructive lung disease after allogeneic marrow transplantation. Ann Intern Med 1989; 111: 368-376.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
13. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
14. Cox DR. Regression models and life tables. J Roy Stat Soc 1972; 34: 187-220.
15. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
16. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-vs-host disease after marrow transplantation for leukemia. New Engl J Med 1986; 313: 729-735.
17. Nevill TJ, Shepherd JD, Reece DE et al. Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant 1992; 10: 445-450.
18. O'Donnell MR, Long GD, Parker PM et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 1995; 13: 2973-2979.
19. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-2043.
20. Copelan E, Deeg J. Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. Blood 1992; 80: 1648-1658.
21. Styler MJ, Crilley P, Biggs J et al. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective multi-center analysis. Bone Marrow Transplant 1999; 18: 171-176.
22. Copelan EA, Kapoor N, Berliner M, Tutschka PJ. Bone marrow transplantation without total body irradiation in patients 40 and older. Transplantation 1989; 48: 65-68.
23. 2 in patients with chronic myelogenous leukemia. Blood 1998; 92: 285a.
24. Biaise D, Maraninchi D, Archimbaud E et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Groupe d'Etudes de la Greffe de Moelle Osseuse. Blood 1992; 79: 2578-2582.
25. Ringden O, Ruutu T, Remberger M et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplant Group. Blood 1994; 83: 2723-2730.
26. Copelan EA, Biggs JC, Thompson JM et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 1991; 78: 838-843.
27. Ringden O, Remberger M, Ruutu T et al for the Nordic Bone Marrow Transplantation Group. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Blood 1999; 93: 2196-2201.
28. Copelan EA. Are busulfan-based preparative regimens equivalent, worse, or better than total body irradiation regimens? In: Bolwell BJ (ed). Current Controversies in Bone Marrow Transplantation. Humana Press: Clifton, NJ, 2000, pp 53-67.